Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects.


The lipid lowering agent Gemfibrozil was tested in 8 normolipidemic subjects during a three-month intake. Plasma triglycerides decreased by 41% and Very Low Density Lipoprotein (VLDL) triglycerides decreased by 54%. The reduction of plasma cholesterol, less marked (by 10%), was due to a decrease of Low Density Lipoprotein by 20% while High Density… (More)


  • Presentations referencing similar topics